The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC

• Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

Locations
United States
Pennsylvania
Abington Memorial Hospital
RECRUITING
Abington
Jefferson Health Northeast
RECRUITING
Philadelphia
Thomas Jefferson University Hospital
RECRUITING
Philadelphia
Asplundh Cancer Pavilion at Jefferson Health
RECRUITING
Willow Grove
Contact Information
Primary
Tyler Grenda, MD
Tyler.grenda@jefferson.edu
215-955-5562
Time Frame
Start Date: 2022-08-31
Estimated Completion Date: 2029-01-01
Participants
Target number of participants: 100
Treatments
Active_comparator: Group I (pulmonary vein first approach procedure)
Patients undergo pulmonary vein first approach surgical procedure on day of surgery.
Active_comparator: Group II (pulmonary artery first surgical procedure)
Patients undergo pulmonary artery first approach surgical procedure on day of surgery.
Sponsors
Leads: Thomas Jefferson University

This content was sourced from clinicaltrials.gov